Retatrutide and Fertility
Retatrutide and fertility is a critical topic for men and women of reproductive age considering weight loss treatment. While retatrutide itself must be discontinued before pregnancy, the weight loss it produces can dramatically improve fertility in both sexes. Obesity is one of the most common reversible causes of infertility, and the 24% weight loss seen in Phase 2 trials (Jastreboff et al., NEJM 2023) could restore reproductive function in many patients who struggle to conceive.
The relationship between obesity and infertility is well-established and bidirectional. Excess body weight disrupts reproductive hormones, impairs gamete quality, reduces conception rates, and increases pregnancy complications. For couples struggling with infertility, weight loss is often one of the most effective and underutilized interventions. GLP-1 medications like retatrutide offer a path to the significant weight loss needed to restore fertility -- but they come with important timing and safety considerations that every patient must understand.
Critical Reproductive Safety Notice
All GLP-1 medications, including retatrutide, must be discontinued before pregnancy. Retatrutide is not FDA-approved for any indication and has not been studied in pregnancy. Use reliable contraception during treatment. Discontinue at least 2 months before planned conception. If you become pregnant during treatment, stop the medication immediately and contact your healthcare provider. Compounded semaglutide ($99/mo) and tirzepatide ($125/mo) are available now.
Weight Loss and Female Fertility
Obesity impairs female fertility through multiple mechanisms. Excess adipose tissue disrupts the hypothalamic-pituitary-ovarian axis, leading to irregular or absent ovulation. Elevated insulin and androgens (particularly in PCOS) create an inhospitable hormonal environment for conception. Obesity reduces egg quality and endometrial receptivity. And even with conception, obese women face higher rates of miscarriage, gestational diabetes, preeclampsia, and birth complications.
Weight loss of 5-10% can restore ovulatory cycles in many women, reduce miscarriage risk, and improve IVF success rates. The 24% weight loss with retatrutide would be expected to provide dramatic fertility improvement, potentially resolving obesity-related infertility entirely in many cases.
Weight Loss and Male Fertility
Male obesity impairs fertility through reduced testosterone (via aromatization of testosterone to estrogen in fat tissue), impaired sperm quality (reduced count, motility, and morphology), erectile dysfunction and reduced sexual frequency, and increased scrotal temperature from excess fat. Weight loss reverses most of these effects, with testosterone recovery being particularly important. Men do not need to discontinue GLP-1 medications for conception, as these drugs have not shown direct effects on sperm or male reproductive organs.
Treatment Timing and Planning
- Start treatment early: If planning pregnancy in 6-12 months, start weight loss medication now to achieve significant weight loss before discontinuation.
- Discontinue 2+ months before conception: This allows medication clearance and metabolic stabilization.
- Use reliable contraception during treatment: Weight loss can restore fertility unexpectedly -- do not rely on previous anovulation as contraception.
- Consider non-oral contraception: GLP-1 medications may affect oral contraceptive absorption.
- Maintain healthy habits: The lifestyle habits established during treatment (nutrition, exercise) help maintain weight and fertility after medication stops.
Plan Your Path to Parenthood
Compounded semaglutide ($99/mo) and compounded tirzepatide ($125/mo) can help you achieve a healthier weight before conception. Our physicians understand reproductive planning considerations and can help time treatment appropriately.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Retatrutide is not FDA-approved for any indication and has not been studied in pregnancy. All GLP-1 medications must be discontinued before pregnancy. Fertility treatment should be supervised by a reproductive endocrinologist. Do not start or stop any medication without consulting your healthcare provider.
Improve Your Fertility Through Weight Management
Compounded semaglutide from $99/mo. Compounded tirzepatide from $125/mo. Physician-supervised care.
View Treatment OptionsMore on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).